ArticleMaterials today. Bio2026
A microfluidic model of human dental pulp angiogenesis for preclinical drug and biomaterial testing.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Organ-on-chip (OoC) and nano-biomaterials: next generation of precision oral and dental healthcare research.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dental pulp homeostasis and regeneration critically depend on angiogenesis, the formation of new capillaries from preexisting blood vessels. Regenerative endodontics has emerged as a clinical strategy to restore damaged or diseased dental pulp tissues using stem cells, signalling molecules, and scaffolds. Enhanced cell viability and angiogenesis are essential for the success of such regenerative therapies. However, their development, as well as efficient drug and biomaterial testing, is limited by the lack of physiologically relevant models. In this study, we developed a microfluidic model of angiogenesis in the human dental pulp to investigate the effects of drugs and biomaterials commonly used in dentistry. We optimised culture conditions influencing angiogenic sprouting and found that the presence of dental pulp cells and lower fibrin concentrations promoted angiogenesis significantly. Furthermore, static culture conditions enhanced sprouting compared with co- or contra-directional hydrostatic pressure-driven flow. Using this platform, we tested drugs (Paclitaxel and Limantrafin) and biomaterials (HEMA and Emdogain®). The model enabled quantitative imaging of angiogenic sprout growth and assessment of cytotoxicity through analysis of the culture medium. Importantly, the timing of drug exposure proved critical: early treatment inhibited sprout formation, whereas later treatment compromised the stability and viability of established vessels. HEMA (10 mM) resulted in cytotoxicity and compromised vessels, whereas Emdogain (1 mg/ml) showed no cytotoxicity and no significant impact on vessel formation. Paclitaxel efficiently inhibited angiogenesis at low concentrations (50 nM) with low cell death while Limantrafin required high concentrations (1 mM) to inhibit angiogenesis while showing elevated cell death and cytotoxicity. In conclusion, this microfluidic model provides a robust tool for studying fundamental angiogenic processes in the human dental pulp and offers an improved platform for safe and effective drug and biomaterial testing, thereby advancing regenerative endodontic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.